Selective KIT inhibitor KI-328 and HSP90 inhibitor show different potency against the type of KIT mutations recurrently identified in acute myeloid leukemia

International Journal of Hematology

Volumn 92, Issue 4, 2010, Pages 624-633

  Tsujimura, Akane ^a,b   Kiyoi, Hitoshi ^b   Shiotsu, Yukimasa ^c   Ishikawa, Yuichi ^a,b   Mori, Yumiko ^a,b   Ishida, Hiroshi ^c   Toki, Tsutomu ^d   Ito, Etsuro ^d   Naoe, Tomoki ^a  

^a NAGOYA UNIVERSITY GRADUATE SCHOOL OF MEDICINE   (Japan)

^b NAGOYA UNIVERSITY SCHOOL OF MEDICINE   (Japan)

^c KYOWA HAKKO KOGYO CO LTD   (Japan)

^d HIROSAKI UNIVERSITY   (Japan)

Author keywords

HSP90; Inhibitor; KIT; Leukemia; Tyrosine kinase

Indexed keywords

ANTILEUKEMIC AGENT; DASATINIB; FI 197; GELDANAMYCIN; HEAT SHOCK PROTEIN 90 INHIBITOR; IMATINIB; KI 328; KIT KINASE; MUTANT PROTEIN; PROTEIN TYROSINE KINASE; PROTEIN TYROSINE KINASE INHIBITOR; TANESPIMYCIN; UNCLASSIFIED DRUG;

ACUTE GRANULOCYTIC LEUKEMIA; ARTICLE; CANCER INHIBITION; CELL MUTANT; COMPARATIVE STUDY; CONCENTRATION RESPONSE; CONTROLLED STUDY; DRUG POTENCY; ENZYME ASSAY; HUMAN; HUMAN CELL; IN VITRO STUDY; WILD TYPE;

ANTINEOPLASTIC AGENTS; CARBAMATES; CELL LINE, TUMOR; HSP90 HEAT-SHOCK PROTEINS; HUMANS; K562 CELLS; LEUKEMIA, MYELOID, ACUTE; MUTATION; PROTEIN KINASE INHIBITORS; PROTO-ONCOGENE PROTEINS C-KIT; PYRIMIDINES;

EID: 78549277136     PISSN: 09255710     EISSN: None     Source Type: Journal    
DOI: 10.1007/s12185-010-0692-8     Document Type: Article

References (43)

1. Y Yarden WJ Kuang T Yang-Feng L Coussens S Munemitsu TJ Dull E Chen J Schlessinger U Francke A Ullrich 1987 Human proto-oncogene c-kit: a new cell surface receptor tyrosine kinase for an unidentified ligand EMBO J 6 3341 3351 1:CAS:528:DyaL1cXhtVOhtLs%3D 2448137
2. W Matthews CT Jordan GW Wiegand D Pardoll IR Lemischka 1991 A receptor tyrosine kinase specific to hematopoietic stem and progenitor cell-enriched populations Cell 65 1143 1152 1:CAS:528:DyaK38Xht1agsbs%3D 10.1016/0092-8674(91) 90010-V 1648448
3. VC Broudy 1997 Stem cell factor and hematopoiesis Blood 90 1345 1364 1:CAS:528:DyaK2sXltlOktL8%3D 9269751
4. CD Mol KB Lim V Sridhar H Zou EY Chien BC Sang J Nowakowski DB Kassel CN Cronin DE McRee 2003 Structure of a c-kit product complex reveals the basis for kinase transactivation J Biol Chem 278 31461 31464 1:CAS:528: DC%2BD3sXmsVOnsb0%3D 10.1074/jbc.C300186200 12824176 (Pubitemid 37048320)
5. H Ikeda Y Kanakura T Tamaki A Kuriu H Kitayama J Ishikawa Y Kanayama T Yonezawa S Tarui JD Griffin 1991 Expression and functional role of the proto-oncogene c-kit in acute myeloblastic leukemia cells Blood 78 2962 2968 1:STN:280:DyaK38%2FmtlShsQ%3D%3D 1720040
6. T Furitsu T Tsujimura T Tono H Ikeda H Kitayama U Koshimizu H Sugahara JH Butterfield LK Ashman Y Kanayama, et al. 1993 Identification of mutations in the coding sequence of the proto-oncogene c-kit in a human mast cell leukemia cell line causing ligand-independent activation of c-kit product J Clin Invest 92 1736 1744 1:CAS:528:DyaK2cXivVCntQ%3D%3D 10.1172/JCI116761 7691885
7. S Hirota K Isozaki Y Moriyama K Hashimoto T Nishida S Ishiguro K Kawano M Hanada A Kurata M Takeda, et al. 1998 Gain-of-function mutations of c-kit in human gastrointestinal stromal tumors Science 279 577 580 1:CAS:528: DyaK1cXotVyhsw%3D%3D 10.1126/science.279.5350.577 9438854 (Pubitemid 28067289)
8. J Lennartsson T Jelacic D Linnekin R Shivakrupa 2005 Normal and oncogenic forms of the receptor tyrosine kinase kit Stem Cells 23 16 43 1:CAS:528:DC%2BD2MXhtVygu74%3D 10.1634/stemcells.2004-0117 15625120 (Pubitemid 40105289)
9. R Roskoski Jr 2005 Structure and regulation of Kit protein-tyrosine kinase-the stem cell factor receptor Biochem Biophys Res Commun 338 1307 1315 1:CAS:528:DC%2BD2MXht1egs77N 10.1016/j.bbrc.2005.09.150 16226710 (Pubitemid 41608395)
10. A Beghini P Peterlongo CB Ripamonti L Larizza R Cairoli E Morra C Mecucci 2000 C-kit mutations in core binding factor leukemias Blood 95 726 727 1:STN:280:DC%2BD3c7itlSmtA%3D%3D 10660321
11. NA Speck DG Gilliland 2002 Core-binding factors in haematopoiesis and leukaemia Nat Rev Cancer 2 502 513 1:CAS:528:DC%2BD38XkvFKltLg%3D 10.1038/nrc840 12094236
12. Y Ishikawa H Kiyoi A Tsujimura S Miyawaki Y Miyazaki K Kuriyama M Tomonaga T Naoe 2009 Comprehensive analysis of cooperative gene mutations between class I and class II in de novo acute myeloid leukemia Eur J Haematol 83 90 98 1:CAS:528:DC%2BD1MXpvFehs7o%3D 10.1111/j.1600-0609.2009.01261.x 19309322
13. S Frohling C Scholl DG Gilliland RL Levine 2005 Genetics of myeloid malignancies: pathogenetic and clinical implications J Clin Oncol 23 6285 6295 1:CAS:528:DC%2BD2MXhtFWntbjE 10.1200/JCO.2005.05.010 16155011 (Pubitemid 46218838)
14. S Schnittger TM Kohl T Haferlach W Kern W Hiddemann K Spiekermann C Schoch 2006 KIT-D816 mutations in AML1-ETO-positive AML are associated with impaired event-free and overall survival Blood 107 1791 1799 1:CAS:528:DC%2BD28XitFChsLY%3D 10.1182/blood-2005-04-1466 16254134 (Pubitemid 43289355)
15. R Cairoli A Beghini G Grillo G Nadali F Elice CB Ripamonti P Colapietro M Nichelatti L Pezzetti M Lunghi, et al. 2006 Prognostic impact of c-KIT mutations in core binding factor leukemias: an Italian retrospective study Blood 107 3463 3468 1:CAS:528:DC%2BD28Xkt1Git7Y%3D 10.1182/blood-2005-09-3640 16384925
16. P Paschka G Marcucci AS Ruppert K Mrozek H Chen RA Kittles T Vukosavljevic D Perrotti JW Vardiman AJ Carroll, et al. 2006 Adverse prognostic significance of KIT mutations in adult acute myeloid leukemia with inv(16) and t(8;21): a Cancer and Leukemia Group B Study J Clin Oncol 24 3904 3911 1:CAS:528:DC%2BD28Xps1SitrY%3D 10.1200/JCO.2006.06.9500 16921041 (Pubitemid 46630738)
17. MC Heinrich CD Blanke BJ Druker CL Corless 2002 Inhibition of KIT tyrosine kinase activity: a novel molecular approach to the treatment of KIT-positive malignancies J Clin Oncol 20 1692 1703 1:CAS:528: DC%2BD38XivFeit7o%3D 10.1200/JCO.20.6.1692 11896121 (Pubitemid 34260552)
18. Y Ma S Zeng DD Metcalfe C Akin S Dimitrijevic JH Butterfield G McMahon BJ Longley 2002 The c-KIT mutation causing human mastocytosis is resistant to STI571 and other KIT kinase inhibitors: kinases with enzymatic site mutations show different inhibitor sensitivity profiles than wild-type kinases and those with regulatory-type mutations Blood 99 1741 1744 1:CAS:528:DC%2BD38XhvFyqurg%3D 10.1182/blood.V99.5.1741 11861291 (Pubitemid 34533049)
19. AS Corbin IJ Griswold P La Rosee KW Yee MC Heinrich CL Reimer BJ Druker MW Deininger 2004 Sensitivity of oncogenic KIT mutants to the kinase inhibitors MLN518 and PD180970 Blood 104 3754 3757 1:CAS:528:DC%2BD2cXhtVGltb3O 10.1182/blood-2004-06-2189 15304388 (Pubitemid 39564454)
20. MM Schittenhelm S Shiraga A Schroeder AS Corbin D Griffith FY Lee C Bokemeyer MW Deininger BJ Druker MC Heinrich 2006 Dasatinib (BMS-354825), a dual SRC/ABL kinase inhibitor, inhibits the kinase activity of wild-type, juxtamembrane, and activation loop mutant KIT isoforms associated with human malignancies Cancer Res 66 473 481 1:CAS:528:DC%2BD28XhsFWltw%3D%3D 10.1158/0008-5472.CAN-05-2050 16397263 (Pubitemid 43166056)
21. J Gotlib C Berube JD Growney CC Chen TI George C Williams T Kajiguchi J Ruan SL Lilleberg JA Durocher, et al. 2005 Activity of the tyrosine kinase inhibitor PKC412 in a patient with mast cell leukemia with the D816V KIT mutation Blood 106 2865 2870 1:CAS:528:DC%2BD2MXhtFantbfM 10.1182/blood-2005-04- 1568 15972446 (Pubitemid 41510766)
22. J Pan A Quintas-Cardama HM Kantarjian C Akin T Manshouri P Lamb JE Cortes A Tefferi FJ Giles S Verstovsek 2007 EXEL-0862, a novel tyrosine kinase inhibitor, induces apoptosis in vitro and ex vivo in human mast cells expressing the KIT D816V mutation Blood 109 315 322 1:CAS:528:DC%2BD2sXivVyru70%3D 10.1182/blood-2006-04-013805 16912224 (Pubitemid 46053072)
23. KS Gajiwala JC Wu J Christensen GD Deshmukh W Diehl JP DiNitto JM English MJ Greig YA He SL Jacques, et al. 2009 KIT kinase mutants show unique mechanisms of drug resistance to imatinib and sunitinib in gastrointestinal stromal tumor patients Proc Natl Acad Sci USA 106 1542 1547 1:CAS:528: DC%2BD1MXhvVOms78%3D 10.1073/pnas.0812413106 19164557
24. P Dubreuil S Letard M Ciufolini L Gros M Humbert N Casteran L Borge B Hajem A Lermet W Sippl, et al. 2009 Masitinib (AB1010), a potent and selective tyrosine kinase inhibitor targeting KIT PLoS One 4 e7258 10.1371/journal.pone. 0007258 19789626
25. TJ Abrams LB Lee LJ Murray NK Pryer JM Cherrington 2003 SU11248 inhibits KIT and platelet-derived growth factor receptor beta in preclinical models of human small cell lung cancer Mol Cancer Ther 2 471 478 1:CAS:528: DC%2BD3sXkvVersbw%3D 12748309
26. E Wardelmann N Thomas S Merkelbach-Bruse K Pauls N Speidel R Buttner H Bihl CC Leutner T Heinicke P Hohenberger 2005 Acquired resistance to imatinib in gastrointestinal stromal tumours caused by multiple KIT mutations Lancet Oncol 6 249 251 1:CAS:528:DC%2BD2MXjtlWjtLY%3D 10.1016/S1470-2045(05)70097-8 15811621 (Pubitemid 40450717)
27. G Fumo C Akin DD Metcalfe L Neckers 2004 17-Allylamino-17- demethoxygeldanamycin (17-AAG) is effective in down-regulating mutated, constitutively activated KIT protein in human mast cells Blood 103 1078 1084 1:CAS:528:DC%2BD2cXhtVaksL4%3D 10.1182/blood-2003-07-2477 14551138 (Pubitemid 38129574)
28. S Bauer LK Yu GD Demetri JA Fletcher 2006 Heat shock protein 90 inhibition in imatinib-resistant gastrointestinal stromal tumor Cancer Res 66 9153 9161 1:CAS:528:DC%2BD28Xps1aiu74%3D 10.1158/0008-5472.CAN-06-0165 16982758 (Pubitemid 44521135)
29. H Ishida S Isami T Matsumura H Umehara Y Yamashita J Kajita E Fuse H Kiyoi T Naoe S Akinaga, et al. 2008 Novel and orally active 5-(1,3,4-oxadiazol- 2-yl)pyrimidine derivatives as selective FLT3 inhibitors Bioorg Med Chem Lett 18 5472 5477 1:CAS:528:DC%2BD1cXht1Cqs7%2FL 10.1016/j.bmcl.2008.09.031 18835166
30. T Toki R Kanezaki S Adachi H Fujino G Xu T Sato K Suzuki H Tauchi M Endo E Ito 2009 The key role of stem cell factor/KIT signaling in the proliferation of blast cells from Down syndrome-related leukemia Leukemia 23 95 103 1:CAS:528:DC%2BD1MXkvVaqtQ%3D%3D 10.1038/leu.2008.267 18830255
31. R Foster E Byrnes C Meldrum R Griffith G Ross E Upjohn A Braue R Scott G Varigos P Ferrao, et al. 2008 Association of paediatric mastocytosis with a polymorphism resulting in an amino acid substitution (M541L) in the transmembrane domain of c-KIT Br J Dermatol 159 1160 1169 1:STN:280: DC%2BD1cjmslenuw%3D%3D 18795925
32. H Kiyoi Y Shiotsu K Ozeki S Yamaji H Kosugi H Umehara M Shimizu H Arai K Ishii S Akinaga, et al. 2007 A novel FLT3 inhibitor FI-700 selectively suppresses the growth of leukemia cells with FLT3 mutations Clin Cancer Res 13 4575 4582 1:CAS:528:DC%2BD2sXotlGqu7Y%3D 10.1158/1078-0432.CCR-07-0225 17671144 (Pubitemid 47219728)
33. Y Shiotsu H Kiyoi Y Ishikawa R Tanizaki M Shimizu H Umehara K Ishii Y Mori K Ozeki Y Minami, et al. 2009 KW-2449, a novel multikinase inhibitor, suppresses the growth of leukemia cells with FLT3 mutations or T315I-mutated BCR/ABL translocation Blood 114 1607 1617 1:CAS:528:DC%2BD1MXhtVyiurrP 10.1182/blood-2009-01-199307 19541823
34. Y Minami H Kiyoi Y Yamamoto K Yamamoto R Ueda H Saito T Naoe 2002 Selective apoptosis of tandemly duplicated FLT3-transformed leukemia cells by Hsp90 inhibitors Leukemia 16 1535 1540 1:CAS:528:DC%2BD38Xls1WqsLY%3D 10.1038/sj.leu.2402558 12145695
35. MJ Frost PT Ferrao TP Hughes LK Ashman 2002 Juxtamembrane mutant V560GKit is more sensitive to imatinib (STI571) compared with wild-type c-kit whereas the kinase domain mutant D816VKit is resistant Mol Cancer Ther 1 1115 1124 1:CAS:528:DC%2BD3sXmtFamsQ%3D%3D 12481435
36. NP Shah C Tran FY Lee P Chen D Norris CL Sawyers 2004 Overriding imatinib resistance with a novel ABL kinase inhibitor Science 305 399 401 1:CAS:528:DC%2BD2cXls1egtrY%3D 10.1126/science.1099480 15256671 (Pubitemid 38938156)
37. A Orfao AC Garcia-Montero L Sanchez L Escribano 2007 Recent advances in the understanding of mastocytosis: the role of KIT mutations Br J Haematol 138 12 30 1:CAS:528:DC%2BD2sXos12hurc%3D 10.1111/j.1365-2141.2007.06619.x 17555444 (Pubitemid 46889785)
38. L Whitesell SL Lindquist 2005 HSP90 and the chaperoning of cancer Nat Rev Cancer 5 761 772 1:CAS:528:DC%2BD2MXhtVGjs7bF 10.1038/nrc1716 16175177 (Pubitemid 41400776)
39. SK Wandinger K Richter J Buchner 2008 The Hsp90 chaperone machinery J Biol Chem 283 18473 18477 1:CAS:528:DC%2BD1cXnsl2rtb0%3D 10.1074/jbc.R800007200 18442971
40. JS Isaacs W Xu L Neckers 2003 Heat shock protein 90 as a molecular target for cancer therapeutics Cancer Cell 3 213 217 1:CAS:528:DC%2BD3sXislOrtb8%3D 10.1016/S1535-6108(03)00029-1 12676580 (Pubitemid 37443877)
41. D Mahalingam R Swords JS Carew ST Nawrocki K Bhalla FJ Giles 2009 Targeting HSP90 for cancer therapy Br J Cancer 100 1523 1529 1:CAS:528:DC%2BD1MXlslChtrY%3D 10.1038/sj.bjc.6605066 19401686
42. U Banerji 2009 Heat shock protein 90 as a drug target: some like it hot Clin Cancer Res 15 9 14 1:CAS:528:DC%2BD1MXhs1Cjug%3D%3D 10.1158/1078-0432.CCR- 08-0132 19118027
43. M Zhao H Kiyoi Y Yamamoto M Ito M Towatari S Omura T Kitamura R Ueda H Saito T Naoe 2000 In vivo treatment of mutant FLT3-transformed murine leukemia with a tyrosine kinase inhibitor Leukemia 14 374 378 1:CAS:528: DC%2BD3cXit1aksbg%3D 10.1038/sj.leu.2401680 10720129